BIOMAT Database Logo BIOMAT Database Logo

Preclinical pharmacokinetics of the antitumor antibiotic deshydroxy-sparsomycin in beagle dogs. 1988

Z Zylicz, and D J Wagener, and M Garzotto, and T B Vree, and E van der Kleijn, and L A van den Broek, and H C Ottenheijm
Department of Internal Medicine, St. Radbound University Hospital, Nijmegen, The Netherlands.

Sparsomycin (Sm) is a well known inhibitor of protein synthesis with anticancer potential. In order to minimize toxicity of this drug and increase its activity, several analogues were synthesized. Deshydroxy-Sm (dSm) appeared to be a good candidate for further investigations because of its lower toxicity and significantly higher antitumor activity in several ascitic tumors in mice. Pharmacokinetic evaluation in beagle dogs was performed using either single iv bolus or continuous infusion administrations. The drug was eliminated with a terminal t1/2 beta of 0.8 +/- 0.08 hours (48 +/- 5 minutes). The mean volume of distribution was 0.4 +/- 0.06 l.kg-1. The mean total body clearance was 6.4 +/- 0.8 ml.min-1.kg-1. The drug is eliminated mainly by the kidneys (54%). Active tubular secretion and active tubular reabsorption of the drug were observed. The pharmacokinetics was linear until the lethal dose. The results of this study provided additional data useful in selection of potentially useful analogues for further preclinical studies.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D013033 Sparsomycin An antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems.

Related Publications

Z Zylicz, and D J Wagener, and M Garzotto, and T B Vree, and E van der Kleijn, and L A van den Broek, and H C Ottenheijm
Pyrimidinylpropenamides as antitumor agents. Analogues of the antibiotic sparsomycin.
March 1977, Journal of medicinal chemistry,
Z Zylicz, and D J Wagener, and M Garzotto, and T B Vree, and E van der Kleijn, and L A van den Broek, and H C Ottenheijm
[Pharmacokinetics of genistein in beagle dogs].
September 2003, Yao xue xue bao = Acta pharmaceutica Sinica,
Z Zylicz, and D J Wagener, and M Garzotto, and T B Vree, and E van der Kleijn, and L A van den Broek, and H C Ottenheijm
[Pharmacokinetics of hylotelephin in Beagle dogs].
July 2006, Yao xue xue bao = Acta pharmaceutica Sinica,
Z Zylicz, and D J Wagener, and M Garzotto, and T B Vree, and E van der Kleijn, and L A van den Broek, and H C Ottenheijm
Pharmacokinetics of Riluzole in Beagle Dogs.
January 2019, Drug research,
Z Zylicz, and D J Wagener, and M Garzotto, and T B Vree, and E van der Kleijn, and L A van den Broek, and H C Ottenheijm
Pharmacokinetics of tildipirosin in beagle dogs.
February 2018, Journal of veterinary pharmacology and therapeutics,
Z Zylicz, and D J Wagener, and M Garzotto, and T B Vree, and E van der Kleijn, and L A van den Broek, and H C Ottenheijm
[Pharmacokinetics of triptolide in Beagle dogs].
January 2007, Yao xue xue bao = Acta pharmaceutica Sinica,
Z Zylicz, and D J Wagener, and M Garzotto, and T B Vree, and E van der Kleijn, and L A van den Broek, and H C Ottenheijm
Pharmacokinetics of intravenous nitrosylcobalamin, an antitumor agent, in healthy Beagle dogs: a pilot study.
September 2012, Anticancer research,
Z Zylicz, and D J Wagener, and M Garzotto, and T B Vree, and E van der Kleijn, and L A van den Broek, and H C Ottenheijm
The pharmacokinetics of HI-6 in beagle dogs.
January 1983, Biopharmaceutics & drug disposition,
Z Zylicz, and D J Wagener, and M Garzotto, and T B Vree, and E van der Kleijn, and L A van den Broek, and H C Ottenheijm
Quantitative spectrophotometric papergram assays. II. Sparsomycin, a new antitumor antibiotic.
March 1963, Journal of pharmaceutical sciences,
Z Zylicz, and D J Wagener, and M Garzotto, and T B Vree, and E van der Kleijn, and L A van den Broek, and H C Ottenheijm
[Pharmacokinetics of m-nifedipine in Beagle dogs].
August 2004, Yao xue xue bao = Acta pharmaceutica Sinica,
Copied contents to your clipboard!